Related Experiment Video

Updated: Mar 14, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K

Pharmacological Treatment and Cognition in Bipolar I Disorder: Evidence From a Prospective Study in India

Bhavya Bhavya1, Ajay Kumar Shukla1, Abhijit Rozatkar2

  • 1of Department Pharmacology.

Journal of Clinical Psychopharmacology
|March 13, 2026
PubMed

Insights

Routine pharmacotherapy improved cognitive function in adults with Bipolar I disorder. This study observed significant enhancements in both subjective and objective cognitive measures over a 3- to 4-month period.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Clinical Psychology

Background:

  • Bipolar I disorder frequently presents with persistent cognitive dysfunction.
  • The impact of routine pharmacotherapy on cognition in euthymic patients is not well-established.

Purpose of the Study:

  • To investigate short-term changes in cognitive functioning in euthymic Bipolar I disorder patients undergoing standard pharmacological treatment.
  • To assess both subjective and objective cognitive performance.

Main Methods:

  • Prospective observational study involving 51 adults with Bipolar I disorder in euthymia.
  • Cognitive assessments included the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) and Montreal Cognitive Assessment (MoCA) at baseline and 3-4 months.
  • Medication regimens, adherence, and clinical variables were monitored.

Main Results:

  • Significant improvements in COBRA scores (P<0.001) and MoCA scores (P<0.001) were observed.
  • The proportion of participants with normal cognition on MoCA increased from 42% to 78%.
  • Cognitive impairment defined by COBRA decreased from 20% to 6%.

Conclusions:

  • Routine pharmacological treatment is linked to short-term cognitive enhancement in Bipolar I disorder patients.
  • Findings suggest potential benefits of pharmacotherapy for cognitive function, though causality is not established.
Abstract

Keywords:
COBRAMoCAbipolar disorder Icognitioneuthymiapharmacotherapy

More Related Videos

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

956
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.8K

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
726
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
649
Bipolar Disorder01:30

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
1.3K
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
364
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K